Table 1.

IgA/IgG Env ratio significantly correlates with increased risk of infection (decreased vaccine efficacy)

Envelope protein/peptide	Odds ratio			P value
	IgA	IgG	IgA/IgG	IgA	IgG	IgA/IgG
Vaccine strain clade AE.A244gp120*	1.28	0.72	1.58	ns	0.03	<0.01
Env panel IgA primary score*,†	1.39	0.78	1.59	0.05	ns	<0.01
CRF01 AE.C1 peptide	1.69	0.85	1.79	<0.001	ns	<0.001
Clade A.1ConEnv gp140	1.57	0.87	1.66	<0.01	ns	<0.01
Con6 gp120	1.01	0.90	1.06	ns	ns	ns
Non-HIV‡ HSV gD peptide	1.01	1.02	1.01	ns	ns	ns

The odds ratio (univariate) for HIV-1 Env IgA and IgG binding to Env panel for the RV144 case control study are shown. As part of the RV144 correlates analyses, we previously reported the odds ratio and P values for the risk of infection for Env IgG and Env IgA measurements individually (2). For the two HIV-1 Env IgA responses with the strongest odds ratio for increased risk of infection (CRF01 AE.C1 peptide and A1.Con gp140), there was an increase in the odds ratio when the IgA/IgG ratio was measured (compared with Env IgA alone), although the P value was unchanged (P < 0.001; P = 0.0004 for both IgA alone and IgA/IgG ratio). Significant P values with increased odds ratio (increased risk of infection) are shown. ns, not significant.

^*Measurements that become significantly correlated with increased risk of infection when examined as a ratio of IgA to IgG Env binding.

^†Env IgA breadth score (univariate analysis) as reported (2). The multivariate analysis of this same breadth IgA score had an odds ratio of 1.54 (P = 0.03). Pink indicates significant correlation with increased risk of infection (decreased vaccine efficacy). Gray indicates significant correlation with decreased risk of infection.

^‡HSV gD peptide that was present in the gp120 boost of vaccine.